Imricor Medical Systems (ASX:IMR) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IMR 주식 개요

의료 기기 회사인 Imricor Medical Systems, Inc.는 미국에서 심장 카테터 절제술을 위한 자기공명영상(MRI) 호환 제품을 설계, 제조, 판매 및 유통하는 회사입니다.

IMR 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	2/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

수익은 연간 72.44% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $616K )

마이너스 주주 지분

지난 5년간 매년 수익이 17.6% 씩 감소했습니다.

지난 1년 동안 주주가 희석되었습니다.

+ 1 더 많은 위험

Imricor Medical Systems, Inc. 경쟁사

ImpediMed

ASX:IPD

AU$129.5m

Optiscan Imaging

ASX:OIL

AU$183.8m

CurveBeam AI

ASX:CVB

AU$78.4m

Cyclopharm

ASX:CYC

AU$186.2m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Imricor Medical Systems
과거 주가
현재 주가	AU$0.57
52주 최고치	AU$0.83
52주 최저치	AU$0.40
베타	0.26
11개월 변경	27.78%
3개월 변경 사항	19.79%
1년 변경 사항	36.90%
33년 변화	-71.39%
5년 변화	n/a
IPO 이후 변화	-60.34%

최근 뉴스 및 업데이트

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

May 08

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

May 08

We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully

Jan 24

What Is The Ownership Structure Like For Imricor Medical Systems, Inc. (ASX:IMR)?

Dec 02

What You Need To Know About Imricor Medical Systems, Inc.'s (ASX:IMR) Investor Composition

Aug 18

Analysts Expect Breakeven For Imricor Medical Systems, Inc. (ASX:IMR)

Jun 25

주주 수익률

	IMR	AU Medical Equipment	AU 마켓
7D	-3.8%	-0.2%	0.04%
1Y	36.9%	24.2%	9.1%

수익률 대 산업: IMR 지난 1년 동안 24.1 %를 반환한 Australian Medical Equipment 산업을 초과했습니다.

수익률 대 시장: IMR 지난 1년 동안 9.6 %를 반환한 Australian 시장을 초과했습니다.

가격 변동성

Is IMR's price volatile compared to industry and market?
IMR volatility
IMR Average Weekly Movement	7.4%
Medical Equipment Industry Average Movement	9.7%
Market Average Movement	8.3%
10% most volatile stocks in AU Market	16.7%
10% least volatile stocks in AU Market	3.2%

안정적인 주가: IMR 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: IMR 의 주간 변동성( 9% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2006	n/a	Steve Wedan	www.imricor.com

는 미국에서 심장 카테터 절제술을 위한 자기공명영상(MRI) 호환 제품을 설계, 제조, 판매 및 유통하는 의료 기기 회사입니다. 이 회사의 주요 제품으로는 EP 레코딩 시스템과 심장 자극기인 어드밴티지-MR EP 레코더/자극기 시스템이 있습니다. 또한 제1형 심방 조동 치료에 사용되는 Vision-MR 절제 카테터와 MR 스캔 시 전도성 패드에 유도되는 와전류를 최소화하는 데 사용되는 Vision-MR 분산 전극도 이 회사의 제품입니다.

Imricor Medical Systems, Inc. 기본 사항 요약

Imricor Medical Systems 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IMR 기본 통계
시가총액	AU$125.78m
수익(TTM)	-AU$33.93m
수익(TTM)	AU$923.04k

126.4x

P/S 비율

-3.4x

P/E 비율

IMR 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IMR 손익 계산서(TTM)
수익	US$615.57k
수익 비용	US$1.73m
총 이익	-US$1.12m
기타 비용	US$21.51m
수익	-US$22.63m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.11
총 마진	-181.27%
순이익 마진	-3,675.61%
부채/자본 비율	-101.1%

IMR 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IMR 주식 개요

보상

위험 분석

Imricor Medical Systems, Inc. 경쟁사

ASX:IPD

AU$129.5m

ASX:OIL

AU$183.8m

ASX:CVB

AU$78.4m

ASX:CYC

AU$186.2m

가격 내역 및 성능

최근 뉴스 및 업데이트

New major risk - Revenue and earnings growth

Independent Non-Executive Director recently bought AU$73k worth of stock

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

Imricor Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024

Imricor Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of AUD 15.135297 million.

Recent updates

New major risk - Revenue and earnings growth

Independent Non-Executive Director recently bought AU$73k worth of stock

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now

Imricor Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024

Imricor Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of AUD 15.135297 million.

Insufficient new directors

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.12 loss in FY 2022)

Imricor Medical Systems, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

New major risk - Revenue and earnings growth

Imricor Medical Systems, Inc. has filed a Follow-on Equity Offering in the amount of AUD 15 million.

First half 2023 earnings released: US$0.061 loss per share (vs US$0.068 loss in 1H 2022)

New major risk - Revenue and earnings growth

New major risk - Share price stability

Imricor Medical Systems, Inc. announced that it has received AUD 2.861607 million in funding

Imricor Medical Systems, Inc. to Report First Half, 2023 Results on Aug 23, 2023

Imricor Medical Systems, Inc. announced that it has received AUD 1.457143 million in funding

Does Imricor Medical Systems (ASX:IMR) Have A Healthy Balance Sheet?

New minor risk - Share price stability

Key Executive recently bought AU$195k worth of stock

Full year 2022 earnings: Revenues miss analyst expectations

Imricor Medical Systems, Inc. to Report Fiscal Year 2022 Results on Feb 22, 2023

Imricor Medical Systems, Inc. Receives IDE Approval from US FDA

Forecast to breakeven in 2025

Imricor Medical Systems, Inc. Receives the First of Two Required Approvals to Commence the Vision-MR Ablation of VT or VISABL-VT Clinical Trial

Imricor Medical Systems, Inc. announced that it expects to receive $5 million in funding from KAHR Foundation

President recently bought AU$76k worth of stock

President recently bought AU$76k worth of stock

Imricor Medical Systems, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Imricor Medical Systems, Inc. Submits Application for Approval to Commence A Real-Time iCMR-Guided Ventricular Tachycardia (VT) Ablation Clinical Trial

Imricor Medical Systems, Inc. announced that it has received AUD 2.947049 million in funding

First half 2022 earnings released: US$0.068 loss per share (vs US$0.079 loss in 1H 2021)

Imricor Medical Systems, Inc. to Report First Half, 2022 Results on Aug 25, 2022

Imricor Medical Systems, Inc. to Report Q4, 2022 Results on Jul 28, 2022

Here's Why Imricor Medical Systems (ASX:IMR) Must Use Its Cash Wisely

Imricor Medical Systems, Inc. Completes its Preclinical Work to Support Submission for Approval to Initiate VT Clinical Trial in Europe

Imricor Medical Systems, Inc., Annual General Meeting, May 03, 2022

Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 57%

Imricor Medical Systems, Inc. Announces Executive Changes

Consensus forecasts updated

Imricor Medical Systems, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Imricor Medical Systems, Inc. Files Application for an Investigational Device Exemption from US Food and Drug Administration

First half 2021 earnings released: US$0.079 loss per share (vs US$0.056 loss in 1H 2020)

No longer forecast to breakeven

Consensus forecasts updated

We're Hopeful That Imricor Medical Systems (ASX:IMR) Will Use Its Cash Wisely

Non-Executive Director has left the company

Imricor Medical Systems, Inc. Announces Board Changes

When Will Imricor Medical Systems, Inc. (ASX:IMR) Turn A Profit?

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.22 loss in FY 2019)

Revenue beats expectations

New 90-day low: AU$2.16

Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully

Imricor Medical Systems, Inc. Appoints Gregg Stenzel as COO

Imricor Signs Supply and Sales Agreement with Osypka